% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Verger:845506,
author = {Verger, Antoine and Stoffels, Gabriele and Galldiks,
Norbert and Lohmann, Philipp and Willuweit, Antje and
Neumaier, Bernd and Geisler, Stefanie and Langen,
Karl-Josef},
title = {{I}nvestigation of cis-4-[18{F}]{F}luoro-{D}-{P}roline
{U}ptake in {H}uman {B}rain {T}umors {A}fter {M}ultimodal
{T}reatment},
journal = {Molecular imaging $\&$ biology},
volume = {20},
number = {6},
issn = {1860-2002},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2018-02740},
pages = {1035–1043},
year = {2018},
abstract = {PurposeCis-4-[18F]fluoro-D-proline (D-cis-[18F]FPro) has
been shown to pass the intact blood-brain barrier and to
accumulate in areas of secondary neurodegeneration and
necrosis in the rat brain while uptake in experimental brain
tumors is low. This pilot study explores the uptake behavior
of D-cis-[18F]FPro in human brain tumors after multimodal
treatment.ProceduresIn a prospective study, 27 patients with
suspected recurrent brain tumor after treatment with
surgery, radiotherapy, and/or chemotherapy (SRC) were
investigated by dynamic positron emission tomography (PET)
using D-cis-[18F]FPro (22 high-grade gliomas, one
unspecified glioma, and 4 metastases). Furthermore, two
patients with untreated lesions were included (one
glioblastoma, one reactive astrogliosis). Data were compared
with the results of PET using
O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) which detects
viable tumor tissue. Tracer distribution, mean and maximum
lesion-to-brain ratios (LBRmean, LBRmax), and time-to-peak
(TTP) of the time activity curve (TAC) of tracer uptake were
evaluated. Final diagnosis was determined by histology
(n = 9), clinical follow-up (n = 10), or by [18F]FET
PET (n = 10).ResultsD-cis-[18F]FPro showed high uptake
in both recurrent brain tumors (n = 11) and lesions
classified as treatment-related changes (TRC) only
(n = 16) (LBRmean 2.2 ± 0.7 and 2.1 ± 0.6,
n.s.; LBRmax 3.4 ± 1.2 and 3.2 ± 1.3, n.s.). The
untreated glioblastoma and the lesion showing reactive
astrogliosis exhibited low D-cis-[18F]FPro uptake.
Distribution of [18F]FET and D-cis-[18F]FPro uptake was
discordant in 21/29 cases indicating that the uptake
mechanisms are different.ConclusionThe high accumulation of
D-cis-[18F]FPro in pretreated brain tumors and TRC supports
the hypothesis that tracer uptake is related to cell death.
Further studies before and after therapy are needed to
assess the potential of D-cis-[18F]FPro for treatment
monitoring.},
cin = {INM-3 / INM-4 / INM-5},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
I:(DE-Juel1)INM-5-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29687323},
UT = {WOS:000450173100016},
doi = {10.1007/s11307-018-1197-8},
url = {https://juser.fz-juelich.de/record/845506},
}